The true incidence of the lupus syndrome induced by hydralazine was determined in a longitudinal study of 281 patients consecutively starting hydralazine for hypertension over a 51 month period. Data on the duration of treatment and the maximum dose achieved were examined using life table analysis. After three years' treatment with hydralazine the incidence of the lupus syndrome was 6.7% (95% confidence limits 3-2-10 2%).
Introduction
The peripheral vasodilator hydralazine is commonly added to antihypertensive treatment when a combination of a 3 blocker and a thiazide diuretic has failed to control the blood pressure. Used in this way it proved to be superior to labetalol, minoxidil, methyldopa, and prazosin over a six month period. ' With more prolonged treatment hydralazine, particularly at high dosage, may cause a syndrome resembling systemic lupus erythematosus.I In recent years the maximum daily dose of hydralazine has usually been limited to 200 mg to avoid the lupus syndrome, which has generally been believed to be rare with these lower doses.3 With this dosage limitation the incidence of the lupus syndrome has been estimated at 1l20o4 and 3°,0.5 These figures, however, were derived from cross sectional surveys, which would tend to underestimate the true incidence. 6 We report the incidence of the lupus syndrome in consecutive patients treated with hydralazine for hypertension.
Patients and methods
We studied 281 hypertensive patients who were consecutively prescribed hydralazine in the Sheffield hypertension clinic from October 1978 to December 1982. Hydralazine was used as a third or fourth drug, usually added to a fi blocker plus diuretic. In accordance with the manufacturer's data sheet7 it was started without knowledge of the patients' acetylator phenotype, and the antinuclear factor (titre) was not measured unless there was clinical suspicion of the Table I shows the clinical features of the syndrome. The 14 patients with the syndrome had on average five (range two to eight) of the 10 features analysed. Diagnosis was difficult in one patient (case 7), a woman aged 65. She presented with general ill health and a skin eruption of six weeks' duration. Hydralazine had been started 16 months previously, and she was taking 200 mg daily. The skin lesions were a florid acquired livedo reticularis (fig 1) , erythematous and urticarial lesions, facial telangiectasia, and acrocyanosis. The erythrocyte sedimentation rate was 93 mm in the first hour; the antinuclear factor titre was negative; double stranded DNA titre was 80 (of borderline importance); and she was a rapid acetylator. Cutaneous vasculitis was diagnosed and confirmed by a dermatologist, who considered biopsy to be unnecessary because the features were so typical. All manifestations resolved rapidly after hydralazine was stopped. This patient was atypical because the titre of antinuclear factor was negative and the lupus syndrome is rare in rapid acetylators.
The illness could be termed hydralazine induced cutaneous vasculitis rather than the lupus syndrome, but we considered it to be a variant of the lupus syndrome.
At the time of diagnosis symptoms of the lupus syndrome had been present for a mean of three months (range one to nine). Eight patients were ill enough to require admission to hospital, with a mean stay of 17 days. In addition to the clinical features given in table I six patients had renal impairment during the illness, with urinary abnormalities in four. All the clinical and laboratory features resolved after hydralazine was stopped, with the exception of the high titre of antinuclear factor, which declined but in some cases did not fall to zero. men the syndrome occurred only with 200 mg daily, with an incidence of 4.90o. Women treated with 200 mg daily had a high incidence (19-4°o) , and even in women taking 100 mg daily the incidence was higher (8O0%) than that in men taking 200 mg.
INCIDENCE OF THE LUPUS SYNDROME
Figure 2 (top) shows the life table analysis for all 281 patients. The first case was diagnosed after nine months' treatment and the last case after 40 months. At 40 months the incidence of the lupus syndrome was 72%,, with 950,, confidence limits 3-6-10-8, ' . Figure 2 (bottom) shows the life table analysis according to sex. The incidence at three years was higher in women (ll6o; 950o confidence limits 4-8-18 40o) than in men (2 80,) . Table II shows the relations between sex, duration of treatment, and dose of hydralazine. The incidence of lupus was clearly dose related, with no cases in patients taking 50 mg daily and with incidences of 5-4% in those taking 100 mg daily and 10-4% (95°,, confidence limits 4-3-16.50,,) in those taking 200 mg daily. In The diagnosis of the lupus syndrome was straightforward in all but one case. This patient clearly had hydralazine induced cutaneous vasculitis" but had no other features of the lupus syndrome. In particular, the titre of antinuclear factor was negative and she was a rapid acetylator. Hydralazine induced lupus was thought originally to occur only in slow acetylators.2 It is undoubtedly very rare in rapid acetylators, but cases have been described, '2 and in these the patients also had atypical clinical features.
Hydralazine induced lupus syndrome is a serious adverse reaction. Although the diagnosis was finally straightforward, it was delayed by an average of three months from the onset of symptoms, and sometimes by as long as nine months. This was in patients under the care of doctors with an interest in the condition. The onset is often insidious, and the patient's complaints are often vague. Most patients were ill enough to require admission to hospital, and in at least two patients malignancy was diagnosed initially.13
The importance of this study is that it defines the trie incidence of the lupus syndrome when the drug is used at doses of not more than 200 mg daily. Previous estimates of 1 20 0 and 3005 were derived from cross sectional surveys that probably underestimated the real incidence.6 In the cohort of patients studied here the incidence of the lupus syndrome was 6.7% after three years, and the lower 9500 confidence limit shows that the true incidence is unlikely to be less than 3-2o0 This also suggests that the previous estimates were considerably in error,4 although the doses of hydralazine used in the different populations may be relevant.
The safety of long term hydralazine treatment is clearly related to the sex of the patient and the dose of the drug. A dose of 50 mg daily appears to be safe in both sexes. In men 100 mg daily caused no lupus but there was a 4.99O' incidence with 200 mg daily. In women 100 mg daily was associated with an incidence of 8°,, and 200 Use of alternative drugs-In short term studies hydralazine has proved superior to prazosin, methyldopa, minoxidil, and labetalol.' Prazosin came closest to hydralazine, with similar efficacy and slightly more subjective side effects.' When the subjective side effects of prazosin are weighed against the risk of the lupus syndrome with hydralazine the choice becomes close, and prazosin should probably be preferred in women. Nifedipine, captopril, and endralazine may prove to be suitable alternatives, but satisfactory comparative studies against hydralazine have not been performed.
In conclusion, the incidence of the lupus syndrome induced by hydralazine seems unacceptably high when the drug is prescribed according to current recommendations. The dose should be limited to 100 mg daily, and patients should be followed up closely and advised to report persistent ill health, joint pains, weight loss, rash, chest pain, or any other unexplained symptom. Prazosin should probably be preferred to hydralazine in women.
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